Woman reports retatrutide liver failure after injecting an unapproved vial

An Australian woman has described a case of retatrutide liver failure that began days after she injected an unapproved vial sold under the name of the experimental obesity drug. Megan Hancocks, 32, told ABC News that she spent about a month in hospital and still cannot work, the New York Post reported on 30 October. The vial came from a clinician at a beauty appointment, not from a pharmacy or a trial. What was inside it has not been reported.

What the patient reported

Hancocks said she saw positive posts about peptides online and wanted to lose weight, although she now says she was already small at the time. She told ABC News she struggled to find the product in Australia. Late last year, during a beauty appointment, her clinician offered her peptides said to come from a Chinese manufacturer, paid for in cash. She bought a vial labelled retatrutide and one labelled GHK-Cu, a copper peptide, but never used the second. According to the ABC account, she hesitated because she was unsure how much to take and had no medical advice. She injected the product twice in the last days of December 2025. Within a week she was admitted to hospital with acute liver failure, the report said.

The retatrutide liver failure she describes began with severe jaundice, the yellowing of skin and eyes that occurs when the liver stops clearing a pigment called bilirubin. She also reported constant nausea, vomiting, constipation, a swollen abdomen and fatigue. She stayed in hospital for about a month and recovered enough to avoid a liver transplant, according to the report. Six months later she had been readmitted several times and was taking medicine to support liver repair. She has stopped working and moved in with her mother. She said her treatment has brought weight gain, hair loss and skin sores. "When I look in the mirror I don't see the same person anymore and that's been really hard," she said.

Unapproved retatrutide and the FDA position

Retatrutide is an experimental peptide from Eli Lilly that acts on three hormone receptors, GLP-1, GIP and glucagon. It is still in clinical trials and is not part of any FDA approved drug. Any unapproved retatrutide sold online is therefore not the trial medicine, and its purity, strength and contents are unknown. The FDA says retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. On its page on unapproved GLP-1 drugs, updated on 1 October 2026, the agency lists its actions. FDA warning letters went to telehealth companies that marketed retatrutide, to ingredient distributors that sold it to compounders, and to outsourcing facilities that repackaged it.

The FDA says retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition.

Many products reach buyers as research grade peptides, labelled for research use or not for human consumption. The FDA says it has warned companies that sold semaglutide, tirzepatide, retatrutide, survodutide or mazdutide under such labels while selling directly to consumers with instructions for use. The agency urges people not to buy these products because their quality is unknown and they may be harmful. It also says counterfeit and illegally marketed drugs may hold the wrong ingredient, too much or too little active drug, or none at all. The same risks apply to counterfeit peptides sold in person. Hancocks got her vial through a clinician rather than a website, and the report did not say which Australian rules applied to that sale.

What the trials show and do not show

Demand for retatrutide grows out of its trial results. In the latest trial cited by the Post, people on the lower dose lost an average of 19.5% of body weight and those on the higher dose lost 20.9%, against 9.4% on Ozempic. Peptide Zone covered those results against Ozempic on 28 October, noting that Lilly's figures came from people with type 2 diabetes, that more people stopped retatrutide because of side effects, and that the data had not yet been peer reviewed. The Post also said some trial participants left studies this year because they lost weight too quickly. None of these results describes what happens when someone injects a vial of unknown origin.

Trial participants receive a drug made under controlled conditions, with a known strength, regular checks and doctors who can stop treatment when problems appear. A person who buys a vial outside that system gets none of those protections. Our report on Iceland's syringe sales described customs tests in which many seized peptide vials did not contain what their labels claimed. The FDA has also received adverse event reports linked to dosing errors with compounded semaglutide, some of which required hospital care. Those reports involve approved molecules made outside the normal supply chain. For retatrutide there is no approved product at all, so a buyer has no reference for what a correct vial should hold, and a retatrutide liver failure report cannot be checked against a known product.

What remains unknown

Several basic facts are missing from the public account. The report does not say whether her vial was tested, what it contained, or whether it held retatrutide at all. It does not describe the tests her doctors used to rule out other possible causes of liver injury. Without that work, the case documents a serious illness after an unapproved injection, but it does not show which ingredient, if any, caused it. One account also cannot show how often such injuries occur. The FDA notes that it is not always possible to tell whether a reported adverse event came directly from a drug or from other factors. That caution applies to this retatrutide liver failure report as much as to any other.

The Post also reported that two people in the United States, aged 41 and 49, died after taking knockoff retatrutide, both cases involving cardiac arrest. It did not name a source for those reports, and Peptide Zone could not confirm them. In Australia, University of Queensland researchers have said that people injecting online peptides rarely see themselves as drug injectors, and NSW Health has warned hospitals of rising presentations, as we reported on 27 October. The legitimate routes regulators describe are a prescription from a licensed doctor and a licensed pharmacy, while experimental drugs are available only inside clinical trials. In the United States, patients and clinicians can report suspected reactions to the FDA through its MedWatch program.

Conclusion

This retatrutide liver failure account rests on one patient's description, relayed by ABC News and the New York Post, and the contents of her vial remain unknown. It matches the risks the FDA lists for unapproved products sold outside pharmacies: no checks on identity, strength or purity. Retatrutide remains an experimental drug. Until a regulator approves it, any product sold under that name outside a trial is unapproved.